Prevalence and characterization of treatment‐refractory psoriasis and super‐responders to biologic treatment: a nationwide study

Introduction Treatment with biologics often leads to clearance of psoriasis. However, some patients do repeatedly fail to respond and/or lose an achieved response (treatment refractory) to the biologic, whereas other patients achieve excellent response to one biologic and remain clear of psoriasis f...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the European Academy of Dermatology and Venereology 2022-08, Vol.36 (8), p.1284-1291
Main Authors: Loft, N., Egeberg, A., Rasmussen, M.K., Bryld, L.E., Nissen, C.V., Dam, T.N., Ajgeiy, K.K., Iversen, L., Skov, L.
Format: Article
Language:English
Subjects:
Biological Products - adverse effects
Body Weight
Female
Humans
Male
Middle Aged
Prevalence
Psoriasis
Severity of Illness Index
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction Treatment with biologics often leads to clearance of psoriasis. However, some patients do repeatedly fail to respond and/or lose an achieved response (treatment refractory) to the biologic, whereas other patients achieve excellent response to one biologic and remain clear of psoriasis for several years (super‐responders). Objective To identify and characterize patients with treatment refractory psoriasis and patients who are super‐responders to biologic treatment. Material and methods Patients registered in DERMBIO between January 2007 and November 2019 were included. Patients were categorized as being treatment refractory if they had had treatment failure to ≥3 biologics targeting ≥2 different pathways. Super‐responders were patients treated with their first biologic for minimum 5 years without an absolute psoriasis area and severity index (PASI) > 3 between 6 months and 5 years of treatment. All remaining patients from DERMBIO served as comparators. Results In total, 3280 patients were included with a mean age of 45.0 years. 1221 (37%) of the patients were females. Of the included patients, 214 (6.5%) were categorized as treatment refractory and 207 (6.3%) were categorized as super‐responders. Treatment refractory patients had higher mean body weight (100.6 kg vs. 90.6 kg, P 
ISSN:0926-9959
1468-3083
DOI:10.1111/jdv.18126